The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.

The largest innovations within pharmaceutical development come through new compounds that have unique and novel modes of action. These innovations commonly involve expanding the protein space targeted by pharmaceutical agents. At present, information about drugs and drug targets is available online via public databases such as DrugBank and the Therapeutic Targets Database. However, this information is biased, understandably so, toward established drugs and drug-target interactions. To gain a better overview of the drug-targeted portion of the human proteome and the directions of current drug development, we developed a data set of clinical trial drug-target interactions based on CenterWatch's Drugs in Clinical Trials Database, one of the largest databases of its kind. Our curation identified 475 potentially novel clinical trial drug targets. This review aims to identify trends in drug development based on the potentially novel targets currently being explored in clinical trials.

[1]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[2]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[3]  Jose M Garcia,et al.  Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study , 2012, Supportive Care in Cancer.

[4]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[5]  S. Aldridge.  Toll-like receptor blocker slows beta cell death in type 1 diabetes , 2012, Nature Biotechnology.

[6]  H. Lijnen,et al.  Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity , 2010, Obesity.

[7]  Miguel Medina,et al.  Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib* , 2011, The Journal of Biological Chemistry.

[8]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[9]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[10]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[11]  Michael G. H. McGeary,et al.  Sources of Cancer Research Funding in the United States , 1999 .

[12]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[13]  B. Cha,et al.  Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732. , 2007, Journal of molecular endocrinology.

[14]  K. Herold,et al.  Anti‐CD3 mAbs for treatment of type 1 diabetes , 2009, Diabetes/metabolism research and reviews.

[15]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[16]  Robert Fredriksson,et al.  Mapping the human membrane proteome : a majority of the human membrane proteins can be classified according to function and evolutionary origin , 2015 .

[17]  Milton H. Saier,et al.  TCDB: the Transporter Classification Database for membrane transport protein analyses and information , 2005, Nucleic Acids Res..

[18]  M. Saier.  A Functional-Phylogenetic Classification System for Transmembrane Solute Transporters , 2000, Microbiology and Molecular Biology Reviews.

[19]  K. Śmietana,et al.  Outlook for the next 5 years in drug innovation , 2012, Nature Reviews Drug Discovery.

[20]  J. Silberg,et al.  A transposase strategy for creating libraries of circularly permuted proteins , 2012, Nucleic acids research.

[21]  P. Imming,et al.  Drugs, their targets and the nature and number of drug targets , 2006, Nature Reviews Drug Discovery.

[22]  Esther F. Schmid,et al.  Keynote review: Is declining innovation in the pharmaceutical industry a myth? , 2005, Drug discovery today.

[23]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[24]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[25]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[26]  P. K. Chugh,et al.  Recent advances in the pathophysiology and pharmacological treatment of obesity , 2012, Journal of clinical pharmacy and therapeutics.

[27]  E. Webb.  Enzyme nomenclature 1992. Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes. , 1992 .

[28]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[29]  J. Garrido,et al.  Molecular Neuroscience Review Article Modulation of Gsk-3 as a Therapeutic Strategy on Tau Pathologies Role and Regulation of Gsk-3 Activity , 2022 .

[30]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[31]  M. Dietrich,et al.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons , 2012, Nature Reviews Drug Discovery.

[32]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[33]  Brian M. Smith,et al.  Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization , 2008, Journal of Pharmacology and Experimental Therapeutics.

[34]  J. Drews.  Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.